

Morgan Stanley & Co.
International plc

20 Bank Street
Canary Wharf
London E14 4AD

tel +44 (0)20 7425 8000
fax +44 (0)20 7425 8990
telex 8812564

Morgan Stanley

The Board of Directors
Horizon Therapeutics plc
70 St. Stephen's Green
Dublin 2
D02E2X4
Ireland

18 January 2023

Dear Sirs,

Proposed acquisition of Horizon Therapeutics plc (the "Company") by Amgen Inc. (the "Proposed Transaction")

We refer to the proxy statement (incorporating the scheme document) dated on or about the date of this letter which is intended to be filed by the Company with the U.S. Securities Exchange Commission pursuant to U.S. Securities Act 1933 and sent to (among others) the shareholders of the Company (the "**Scheme Document**"), a final version of which we have been provided with.

The Scheme Document includes a copy of the opinion letter dated December 10, 2022, rendered by Morgan Stanley and Co. LLC ("**Morgan Stanley**") for the benefit of the Board of Directors of the Company (the "**Opinion**"), as well as certain references to Morgan Stanley and the Opinion.

Morgan Stanley hereby gives its consent to the issue of the Scheme Document with the inclusion therein of the Opinion and references to Morgan Stanley's name and the Opinion in the form and context in which they appear.

Our consent is given for the purpose of Rule 23.2 (a) and (d) of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, and for no other purpose.

The letter is for your information only and should not be relied upon by any other person.

Yours faithfully,



David Kitterrick
Managing Director

For and on behalf of
Morgan Stanley & Co. International plc